<DOC>
	<DOCNO>NCT02953652</DOCNO>
	<brief_summary>Phase 2b , open-label , non-randomized , single arm study evaluate safety , efficacy , pharmacokinetics HBI-8000 40 mg BIW patient relapse refractory PTCL ( R/R PTCL ) .</brief_summary>
	<brief_title>Efficacy Safety Oral HBI-8000 Patients With Relapsed Refractory Peripheral T-cell Lymphoma ( PTCL )</brief_title>
	<detailed_description>This Phase 2b , open-label , non-randomized , single arm study evaluate safety , efficacy , pharmacokinetics HBI-8000 40 mg BIW patient relapse refractory PTCL ( R/R PTCL ) . HBI 8000 administer orally approximately 30 minute regular meal twice week . There 3-4 day dose . A cycle define consecutive 28 day . HBI-8000 administration continue disease progression unacceptable toxicity observe despite appropriate dose reduction treatment interruption .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<criteria>1 . Histological cytological diagnosis follow peripheral Tcell lymphoma ( PTCL ) subtypes define WHO classification ( 2008 ) may include : 1 . PTCL , NOS 2 . Angioimmunoblastic Tcell lymphoma ( AITL ) 3 . Anaplastic largecell lymphoma ( ALCL ) , ALK+ 4 . Anaplastic largecell lymphoma ( ALCL ) , ALK− 5 . Enteropathyassociated Tcell lymphoma ( EATL ) 6 . Hepatosplenic Tcell lymphoma 7 . Subcutaneous panniculitislike Tcell lymphoma 2 . Patients least 1 measurable lesion confirm lesion assessment baseline ; evaluable lesion define 1.5 cm great dimension follow image . 3 . Progressive disease receive ≥ 1 prior systemic therapy antitumor agent ( ) . This could include frontline chemotherapy , mogamulizumab , ineligible mogamulizumab , available treatment proven efficacy 4 . Male female , age 20 year old 5 . ECOG Performance Status 02 6 . Life expectancy great 3 month 7 . Meeting follow laboratory criterion : 1 . Absolute Neutrophil Count &gt; 1500/µL independent growth factor support within 7 day start study drug 2 . Platelets &gt; 75,000/µL independent transfusion within 14 day start study drug 3 . Hgb &gt; 8 g/dL independent transfusion within 14 day start study drug 4 . Serum creatinine &lt; 1.5 X ULN 5 . Serum aspartate aminotransferase/glutamyl oxaloacetic transaminase ( AST/SGOT ) alanine aminotransferase/glutamyl pyruvic transaminase ( ALT/SGPT ) less equal 3 X ULN 6 . Serum Bilirubin less equal 1.5 X ULN 8 . Negative serum pregnancy test female childbearing ( reproductive ) potential . Female patient child bear potential must use effective method birth control ( e.g. , hormonal contraceptive , intrauterine device , diaphragm spermicide condom spermicide ) treatment period 1 month thereafter . Males must use effective method birth control ( 2 barrier method ) treatment period 3 month thereafter . Note : Female patient consider woman childbearing potential unless undergone permanent contraception postmenopausal . Postmenopausal define least 12 month without menses medical reason ( e.g. , chemical menopause treatment antimalignant tumor agent ) 9 . Signed informed consent 1 . Male patient QTcF &gt; 450 msec screening , female patient QTcF &gt; 470 msec screen patient congenital long QT syndrome , clinically significant arrhythmia , history congestive heart failure ( New York Heart Association Class III IV ) acute myocardial infarction within 6 month start study drug 2 . Patients know hypersensitivity benzamide class compound component HBI8000 tablets 3 . Patients second malignancy disease study . The exception disease treat curative intent evidence recurrence past 5 year include : 1 . Basal cell carcinoma skin 2 . Squamous cell carcinoma skin 3 . Cervical carcinoma situ 4 . Carcinoma situ breast 5 . An incidental histological finding prostate carcinoma ( TNM stage T1a T1b ) 6 . Earlystage gastric cancer treat endoscopic mucosal resection endoscopic submucosal dissection 4 . Autologous stem cell transplantation within 12 week ( 84 day ) start study drug 5 . Allogeneic stem cell transplantation require immunosuppressant treatment within 21 day start study drug active Graft Versus Host Disease ( GVHD ) 6 . Organ transplantation recipient except hematopoietic stem cell transplantation 7 . Uncontrolled intercurrent infection 8 . Hepatitis B surface antigenpositive , hepatitis C virus antibody positive . In case hepatitis B core antibody and/or hepatitis B surface antibody positive even hepatitis B surface antigennegative , hepatitis B virus DNA test ( realtime PCR measurement ) perform positive , patient exclude study 9 . Any history test positive human immunodeficiency virus ( HIV ) know acquired immunodeficiency syndrome ( AIDS ) 10 . Uncontrolled diabetes mellitus , hypertension , endocrine disorder , bleed disorder 11 . Major surgery radiation therapy within 28 day start study drug 12 . Receiving investigational agent anticancer therapy , within 28 day , nitrosourea mitomycin C within 42 day start study drug 13 . Receiving antibody therapy PTCL within 12 week start study drug 14 . Women breastfeed woman willing stop breastfeeding study treatment period 30 day last dose study drug 15 . Potential noncompliance increase risk base investigator 's judgement</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>